| Database ID | Agent | Target | Cancer Type | Detail |
| DB00976 | ipilimumab | Cytotoxic Tlymphocyte antigen 4 (CTLA4) | melanoma | view |
| DB00977 | nivolumab | programmed death1 | renal cell carcinoma | view |
| DB00978 | trametinib | MEK2
Dual specificity mitogenactivated protein kinase kinase 1 | melanoma | view |
| DB00979 | RO4987655 | MEK | advanced solid tumors | view |
| DB00980 | selumetinib | Dual specificity mitogenactivated protein kinase kinase | melanoma | view |
| DB00981 | olaparib | Poly [ADPribose] polymerase1 | advanced solid tumors | view |
| DB00982 | everolimus | Serine/threonineprotein kinase mTOR | neuroendocrine tumour | view |
| DB00983 | cetuximab | Epidermal growth factor receptor | colorectal cancer | view |
| DB00984 | cetuximab | Epidermal growth factor receptor | breast cancer | view |
| DB00985 | Bevacizumab | Vascular endothelial growth factor | breast cancer | view |
| DB00986 | bevacizumab | Vascular endothelial growth factor | breast cancer | view |
| DB00987 | bevacizumab | Vascular endothelial growth factor | breast cancer | view |
| DB00988 | sorafenib | Vascular endothelial growth factor receptor 1
BRaf protooncogene serine/threonineprotein kinase
Protooncogene tyrosineprotein kinase receptor ret | renal cell carcinoma | view |
| DB00989 | orteronel | 17 alphahydroxylaseC17, 20lyase | prostate cancer | view |
| DB00990 | cetuximab | Epidermal growth factor receptor | colorectal cancer | view |